did that just happen? and what do i do now?
DESCRIPTION
Did that just happen? And What do I do now?. Identifying and Reporting Adverse Events and Protocol Deviations. Elizabeth Mathis, CCRP 18 February 2014. Adverse Events Serious Adverse Events Protocol Deviations. Overview and Objectives. http://www.hhs.gov/ohrp/policy/advevntguid.html. - PowerPoint PPT PresentationTRANSCRIPT
Did that just happen?And What do I do now?
Identifying and Reporting Adverse Events and Protocol
Deviations
Elizabeth Mathis, CCRP18 February 2014
Overview and Objectives
http://www.hhs.gov/ohrp/policy/advevntguid.html
Adverse EventsSerious Adverse Events
Protocol Deviations
Recognize Review Report
Unanticipated Problem Definition
http://www.hhs.gov/ohrp/policy/advevntguid.html
Incident, Experience, or Outcome
Unexpected
Nature
Frequency
Severity
Possibly related to participation in
Research
Places subjects or others at greater
risk of harm
Physical
Psychological
Social
Economic
Unanticipated Problem or Not?Behavioral Study
Collects identifiable info
Illicit drug use and illegal behaviors of college students
Data stored on unencrypted laptop
Laptop stolen from car
Checklist:
⃝� Incident, experience, or outcome?
⃝� Unexpected?
⃝� Related to participation?
⃝� Greater risk of harm?
Unanticipated Problem or Not?Device Intervention Study
Vascular stent placement vs surgery for severe carotid artery stenosisPatient assigned to stent placement study group After procedure, the patient suffers a severe stroke resulting in left-sided paralysis Protocol and ICF indicated a 5-10% chance of stroke for both study groups. The DSMB concludes the occurrence of stroke was expected as well as frequency.
Checklist:
⃝� Incident, experience, or outcome?
⃝� Unexpected?
⃝� Related to participation?
⃝� Greater risk of harm?
Unanticipated Problem or Not?Drug Intervention Study
For essential hypertension testing new anti-hypertensive drug.
Three of the first ten subjects have severe GERD symptoms that began within one week of starting the investigational drug and resolve after drug discontinued.
At beginning of trial, no documented evidence of GERD in protocol and ICF do not describe GERD as risk.
Investigator determines that GERD symptoms were caused by the study drug and warrant modification of the ICF to include GERD as a risk of the research.
Checklist:
⃝� Incident, experience, or outcome?
⃝� Unexpected?
⃝� Related to participation?
⃝� Greater risk of harm?
Adverse EventsDefinition
Unintended or Unfavorable
Temporally Associated Related or Not
Abnormal SignsPhysical Exam Lab Results Symptom Disease
http://www.hhs.gov/ohrp/policy/advevntguid.html
Unanticipated Problem vs.
Adverse Events
http://www.hhs.gov/ohrp/policy/advevntguid.html
A= Adverse Events that are not Unanticipated Problems
C= Unanticipated problems that
are not Adverse Events
B= Adverse Events
that are Unanticipated
Problems
Unanticipated problems
Adverse Events
AE or Not?
Subject # 1On quadruple therapy study for Hepatitis C
ICF states: Decreases in laboratory tests measuring white blood cells, platelets, red blood cells.
AE or Not?Subject # 1
AE or Not?
Subject # 2On triple therapy study for Hepatitis C
Package insert states:
AE or Not?
Subject # 2Progress note for Follow up week 24 visit:
AE or Not?
Subject # 3Device study to detect mucosal oxygenation during
AAA repairFrom ICF:
Physical Risks: Rare
Pain or discomfort upon insertion of the rectal sensor due to an anal fissure (tear), Abscess, Fistula or inflamed hemorrhoid.
Rectal perforation (puncture).
AE or Not?
Subject # 4On triple therapy study for Hepatitis C
http://sv-galena.com/Trip6/201012Bahamas/Part01.html
Serious Adverse EventsDefinition
http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm
Any adverse event that:
Results in death
Is life-threatening
Results in hospitalization
Results in disability
Results in birth defect
Results in intervention to prevent one of
these
SAE or Not?Subject # 5
On quadruple therapy study for Hepatitis C
SAE or Not?Subject #6
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2011/ucm244336.htm
(1) Subject #389204 had Week 8 laboratory tests collected on February 18, 2008, and the corresponding laboratory report that was faxed to your site on February 20, 2008, showed that the subject’s creatinine (CR) level measured 3.2 mg/dL.*
* Normal range is 0.5 -1.2 mg/dL.
Serious Adverse EventsImportant Distinction
Severe Serious
Not Severe
Minor Stroke
Headache Not Serious
Protocol Deviations
Recognize Review Report
Protocol DeviationsDefinition
IRB Approved Protocol
Actual Research Activities
Performed
Protocol DeviationsDefinition
http://research/f/f#Forms-IRBAdmin
Harmed subjects or others
Indicates subjects or others might be at increased risk of
harm
Significantly affects conduct of clinical
trial
Non-compliance with federal
regulations or requirements of IRB
Failure to follow protocol through action or inaction
Change to protocol to eliminate
immediate hazard
Deviation or Not?
Exclusion Criteria #4:Prohibited 6 months prior to Day 0 and throughout the trial (i.e., to last dose to last dose and/or EOT): azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline; fenofibrate orother fibrates; budesonide and other systemic corticosteroids;
Subject # 7On treatment for PBC-related liver enzyme
elevation
Deviation or Not?
Subject # 8On triple therapy for
Hep-C
Deviation or Not?Subject # [Redacted]
• Records of each subject's case history are not all accurate and complete. Specifically, individual subject case history files including source documentation and CRFs contain missing or discrepant information, including, but not limited to the following:
• for subject [redacted] missing documentation of required physical examinations, incomplete or missing documentation regarding the placement of [redacted] and Complications Report or Intercurrent Event Report not completed;
• missing information regarding surgical complications, the number of devices implanted, and device accountability for subject [redacted] and,
• source worksheets and CRFs do not record any information or measurements regarding required evaluations for subjects [redacted]
http://www.fda.gov/ICECI/EnforcementActions/WarningLetter
Overview and Objectives
Adverse Events, Serious Adverse Events, and Protocol Deviations
Recognize Review Report
AE Review
AE Review
SAE Review
Deviation Review
http://www.nia.nih.gov/sites/default/files/protocoldeviationscoreformfillable.pdf
Overview and Objectives
Adverse Event, Serious Adverse Event, and Protocol Deviations
Recognize Review Report
Adverse EventsReporting to IRB
http://research/f/f#Forms-IRBAdmin
Internal Serious Adverse EventsReporting to Sponsor
CTSC Research Guidebook, pg 79
Internal Serious Adverse EventsReporting to IRB
http://research/f/f#Forms-IRBAdmin
Internal Serious Adverse EventsReporting to IRB
http://research/f/f#Forms-IRBAdmin
External Serious Adverse Events
External Serious Adverse EventsReporting to IRB
External Serious Adverse EventsReporting to IRB
Protocol DeviationsReporting to Sponsor
Protocol DeviationsReporting to IRB
http://research/f/f#Forms-IRBAdmin
Protocol DeviationsReporting to IRB
http://research/f/f#Forms-IRBAdmin
RecapAdverse EventsSerious Adverse EventsProtocol Deviations
Recognize Review Report
Resources1. IRB Forms http://research/f/f#Forms-IRBAdmin2.OHRP guidance:
http://www.hhs.gov/ohrp/policy/advevntguid.html3.FDA Warning Letter
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2011/ucm244336.htm
4.SACHRP recommendations on Protocol Deviations: http://www.hhs.gov/ohrp/sachrp/mtgings/2012%20Feb%20Mtg/protocoldeviations.pdf
5. IRB SOPs: http://research.ucdavis.edu/gt/irb-sop